Key Developments: Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

4.12USD
19 Dec 2014
Price Change (% chg)

$-0.05 (-1.20%)
Prev Close
$4.17
Open
$4.20
Day's High
$4.21
Day's Low
$4.01
Volume
1,019,069
Avg. Vol
383,495
52-wk High
$6.87
52-wk Low
$1.94

Search Stocks

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Inc names Chief Executive Officer
Monday, 1 Dec 2014 04:30pm EST 

Idera Pharmaceuticals Inc:Has appointed Vincent J. Milano as Chief Executive Officer, effective today.Says Milano was also appointed to company's Board of Directors.Milano succeeds Sudhir Agrawal.  Full Article

Idera Pharmaceuticals and Parent Project Muscular Dystrophy announce collaboration to advance new treatment approach for Duchenne Muscular Dystrophy
Friday, 7 Nov 2014 07:00am EST 

Idera Pharmaceuticals Inc:Idera Pharmaceuticals and Parent Project Muscular Dystrophy (PPMD) announces collaboration to advance Idera's Toll-like receptor (TLR) technology for the treatment of Duchenne muscular dystrophy.As part of this collaboration, Idera and PPMD intend to work together to conduct preclinical studies and develop a clinical development strategy for an investigational TLR antagonist candidate.In previous preclinical studies in models of Duchenne, treatment with TLR antagonist candidate led to reduction in disease-associated markers of inflammation and improved muscle function.Idera is clinical-stage biopharmaceutical company focused on developing nucleic acid therapeutics for patients with rare and serious diseases.PPMD is the largest and most comprehensive nonprofit organization in the U.S. focused on finding cure for Duchenne.  Full Article

Idera Pharmaceuticals Inc expands pipeline by initiating clinical development of proprietary TLR antagonist candidate IMO-9200
Tuesday, 14 Oct 2014 08:01am EDT 

Idera Pharmaceuticals Inc:Has advanced IMO-9200 into Phase 1 clinical development following acceptance of an Investigational New Drug application by U.S. FDA.In addition, company said presentation of new data that showed IMO-9200 inhibited Toll-like receptor- (TLR-) mediated immune responses in multiple preclinical models.Says these data support development of IMO-9200, synthetic oligonucleotide-based antagonist of TLRs 7, 8 and 9, as potential treatment for autoimmune diseases in which TLRs are over-activated.Idera's pipeline of clinical-stage TLR antagonists also includes IMO-8400, company's lead product candidate currently in development for genetically defined forms of B-cell lymphoma and rare autoimmune diseases.Plans to begin dosing of IMO-9200 in Phase 1 clinical trial in healthy volunteers in Q4.  Full Article

Idera Pharmaceuticals Inc and The Myositis Association join forces to advance the clinical development of TLR Antagonist, IMO-8400, for Treatment of Myositis
Thursday, 7 Aug 2014 08:00am EDT 

Idera Pharmaceuticals Inc:Says collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.Under collaboration, Idera and TMA will develop educational programs and resources for patients and healthcare providers, including interactive online chats, on TLR antagonism and opportunities to participate in upcoming clinical research.Idera plans to initiate a clinical trial of its investigational drug candidate IMO-8400, a first-in-class antagonist of TLRs 7, 8 and 9, in polymyositis and dermatomyositis by the end of 2014.  Full Article

Idera Pharmaceuticals Inc announces agreement with Abbott to develop companion diagnostic for IMO-8400 in genetically defined forms of B-cell Lymphoma
Thursday, 8 May 2014 08:30am EDT 

Idera Pharmaceuticals Inc:Entered into an agreement with Abbott, for the development of an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.Under the agreement, Abbott will develop a test utilizing polymerase chain reaction (PCR) technology to identify the presence of the MYD88 L265P oncogenic mutation in tumor biopsy samples with high sensitivity and specificity.  Full Article

Idera Pharmaceuticals announces positive top-line data in phase 2 trial of IMO-8400
Friday, 28 Mar 2014 07:15am EDT 

Idera Pharmaceuticals Inc:Positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.Primary objective of trial was to evaluate safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400.Trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions.IMO-8400 treatment met secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index (PASI).IMO-8400, which is Idera's lead clinical candidate, is an antagonist of Toll-like receptors (TLRs) 7, 8, and 9.Companies strategy is to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.  Full Article

Idera Pharmaceuticals Inc announces closing of public offering of common stock
Monday, 10 Feb 2014 04:15pm EST 

Idera Pharmaceuticals Inc:Says the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant.Says the gross proceeds to Idera from this offering are expected to be about $40.0 mln, before deducting the underwriting discounts and commissions and other estimated offering expenses.Says Piper Jaffray & Co. and Cowen and Company, LLC acted as joint bookrunning managers for the offering.  Full Article

Idera Pharmaceuticals Inc announces pricing of public offering of common stock
Wednesday, 5 Feb 2014 09:08am EST 

Idera Pharmaceuticals Inc:Says the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock.Says at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.Says gross proceeds to Idera from this offering are expected to be approximately $36 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded.Says it has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,026,188 shares of common stock to cover over-allotments, if any.Says the offering is expected to close on or about February 10, 2014, subject to customary closing conditions.  Full Article

Idera Pharmaceuticals Inc announces public offering of common stock
Tuesday, 4 Feb 2014 04:01pm EST 

Idera Pharmaceuticals Inc:Says it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering.Says Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering.  Full Article

Idera Pharmaceuticals Inc Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
Monday, 30 Sep 2013 04:14pm EDT 

Idera Pharmaceuticals Inc announced the closing of its previously announced underwritten public offering of 13,727,251 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 4,175,975 shares of common stock. The gross proceeds to Idera from this offering are expected to be approximately $27.7 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Idera and excluding the proceeds, if any, from the exercise of the pre-funded warrants. Piper Jaffray & Co. acted as sole manager for the offering.  Full Article

Search Stocks